Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

The oncologist - 1 Jan 2017

Pritchard Kathleen I, Chia Stephen K, Simmons Christine, McLeod Deanna, Paterson Alexander, Provencher Louise, Rayson Daniel

Abstract excerpt

Breast cancer (BC) is the most common malignancy in women worldwide, with approximately two-thirds having hormone receptor-positive (HR+) tumors. New endocrine therapy (ET) strategies include combining ET agents as well as adding inhibitors targeting growth factors, angiogenesis, the mechanistic target of rapamycin, phosphoinositide 3-kinase (PI3K), or cyclin-dependent kinase 4/6 to ET. Level 1 evidence supports...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Estradiol

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fulvestrant

Share to Neoplastic Cells, Circulating

Share to Nitriles

Share to Postmenopause

Share to Pyridines

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 27864574
DOI: 10.1634/theoncologist.2016-0185
PMCID: PMC5313264

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.PMID 27864574Read ↗

Targeted and cytotoxic inhibitors used in the treatment of breast cancerSemantic proximity Read ↗

Post–CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies - A Narrative ReviewSemantic proximity Read ↗

The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.Semantic proximity Read ↗

Targeted therapies for ER+/HER2- metastatic breast cancerSemantic proximity Read ↗

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetySemantic proximity Read ↗

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast CancerSemantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

How I treat endocrine-dependent metastatic breast cancer.Semantic proximity Read ↗

Treatment options for patients with triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.